We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment and teamwork, and so can you. We are currently recruiting for Senior Downstream Scientists to join the Process Development team. The purpose of this role is to plan, execute and report relevant downstream studies or investigations, and to support and supervise other members of the Group as needed to meet the Department objectives. Process Development (PD) is responsible for the development of world-class viral vector manufacturing processes for OXB’s partnered programmes. PD performs a crucial technical role in OXB mission to deliver life-changing gene therapies to patients. Your responsibilities in this role would be: • Involvement in activities ranging from vector production at laboratory and pilot scales, process development and optimisation, technology transfer, and process validation activities associated with the manufacture of new gene therapy vectors. • Responsibility for designing and co-ordinating execution of downstream vector purification and formulation activities for scale-up/scale-down of existing bioprocesses. • Analyse and interpret experimental data and report results to stakeholders (internally to OXB and externally to clients). • Write, revise, review and approve SOPs, technical reports, and risk assessments, where appropriate. • Ensure that the experiments are conducted within the team/project, and their interpretation and reporting are of the highest quality. • Provide direction for a small team and/or projects in line with department and company objectives. • Ensure that all work carried-out in the laboratory is performed efficiently and safely, following OXB HSE procedures. • Carry out such other tasks as are required from time to time for the efficient running of the Company’s business upon request from your line manager or a Director of the Company. We are looking for: • BSc, MSc or PhD (or equivalent) in a relevant Bioscience • Advanced understanding of downstream purification principles and relevant laboratory experience in one or more of the following areas: downstream process development, clarification, chromatography, tangential flow filtration, sterile filtration, product formulation. • Demonstrated process scale up and tech transfer expertise • Experience with the operation of laboratory, pilot or production scale downstream purification processes. • Understanding of laboratory health and safety requirements. • Competency in data capture, reporting and management systems. • Familiar with data analysis software packages such as but not limited to Microsoft Excel, JMP, Design Expert™, GraphPad Prism • High level of familiarity with the current literature relating to research projects. • Excellent written and verbal communication and presentation skills. • Fluency in written and spoken English. About Us: Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise. What’s in it for you: • Highly competitive total reward packages. • Wellbeing programmes. • Development opportunities. • Welcoming, friendly, supportive colleagues. • A diverse and inclusive working environment. • Our values are: Respect, Resiliance, Responsive & Responsible. • State of the art laboratory and manufacturing facilities. Collaborate. Contribute. Change lives. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.